SMRA posted a strong 2Q24 net profit of Rp312b (+83.4% yoy). Following the sale of Summarecon Mall Kelapa Gading to SMIP, the company is considering an IPO for SMIP. We believe SMIP's valuation has the potential to match or surpass SMRA's current market cap. The newly-launched product in Bogor and new township in Tangerang are expected to boost marketing sales in the following months. We maintain BUY on SMRA with a higher target price of Rp865, driven by the potential IPO, rate cuts and marketin...
GREATER CHINA Sector Hong Kong Developers And Landlords Expect the strong performance of the stock market to have a positive impact on property prices. INDONESIA Update Summarecon Agung (SMRA IJ/BUY/Rp700/Target: Rp865) Potential further re-rating from SMIP IPO and more rate cuts. MALAYSIA Update KPJ Healthcare (KPJ MK/HOLD/RM2.07/Target: RM1.90) KPJ’s transformation programme continues to gathe...
GREATER CHINA Economics Economic Activity 2Q24 growth below expectations. Strategy China And Hong Kong Property Sharper property price decline in 1H24 weighing on margins of Chinese developers; upcoming interest rate cut to support value of Hong Kong retail landlords. Update Kingmed Diagnostics (603882 CH/BUY/Rmb38.10/Target: Rmb35.00) 1H24 and 2024 results under pressu...
SMRA successfully achieved presales of Rp1.7t in 1H24, up 7% yoy and contributing to 34% of its 2024 presales target. However, SMRA is optimistic of achieving its 2024 presales target of Rp5t as it will launch new products and townships in 2H24. We estimate 2024-25 NPAT at Rp906b (+18.3% yoy) and Rp944b (+4.3% yoy) respectively. Maintain BUY with a target price of Rp700 as SMRA’s share price is still attractive and could improve due to rate cut expectations.
We believe marketing sales achievement could improve from 2Q24 onwards as new product launches continue to take place. However, BSDE and SMRA could report softer earnings in 2Q24 after a boost in 1Q24 results, while CTRA could deliver a more consistent revenue growth in 2Q24. We also note that property companies are optimistic in achieving their 2024 presales targets as mortgage rates remain attractive despite the recent interest rate hike. Maintain OVERWEIGHT with CTRA as our top pick.
GREATER CHINA Strategy China And Hong Kong Property: Channel checks and observations of Shanghai/Hong Kong primary markets. Results AAC Technologies (2018 HK/BUY/ HK$22.70/ Target: HK$27.20): 2H23: Slight beat in results; outlook in 2024 seems promising. Sunny Optical (2382 HK/BUY/HK$46.85/Target: HK$63.00): 2023: Results in line but forward shipment guidance weaker than expected. Small/Mid Cap Highlights Crystal International (2232 HK/NOT RATED/HK$3.30): 2023: Results in line with guidance, bul...
SMRA reported 4Q23 net profit of Rp113b, falling 48.5% qoq and 64.2% yoy on declining property deliveries and higher contract liabilities interest expenses. On the other hand, 2023 net profit hiked 22.5% yoy to Rp766t, below our and market estimates. Going forward, with 2024 marketing sales target remaining at Rp5.0t and recurring income growth of 10.6% yoy in 2024-25, we expect NPAT of Rp887b (+15.7% yoy) and Rp944b (+6.5% yoy) respectively. Maintain BUY with a lower target price of Rp700.
GoTo GoJek Tokopedia (GOTO IJ/HOLD/Rp67/Target: Rp69): 4Q23: Rp78.8t impairment – investing in scalable business. Summarecon Agung (SMRA IJ/BUY/Rp525/Target: Rp700): 4Q23: Weakness in NPAT as property deliveries fall; results below expectations. TRADERS’ CORNER Merdeka Copper Gold (MDKA IJ): Technical BUY Summarecon Agung (SMRA IJ): Technical BUY
SMRA targets to achieve another round of robust marketing sales of Rp5t in 2024 despite the softness in 2023 marketing sales. VAT incentives will support marketing sales growth in 2024 as most of SMRA’s residential products are eligible for the incentives. We estimate 2023-24 NPAT at Rp822b (+31.4% yoy) and Rp963b (+17.2% yoy) respectively. Solid development revenue will continue in 2023-24 following the high presales achievement in prior years. Maintain BUY with a target price of Rp800.
GREATER CHINA Sector Property: Marginal improvement in secondary market seen in Jan 24; Budget speech to be a focus in near term. INDONESIA Update Summarecon Agung (SMRA IJ/BUY/Rp590/Target: Rp800): Capitalising VAT incentives to drive 2024 marketing sales growth. MALAYSIA Sector Construction: Promising sector backed by stronger replenishment prospects, ramp-up of progress billing and margin improvements. Upgrade to OVERWEIGHT. Update Hume Industries (HUME MK/BUY/RM2.61/Target: RM3.03): Rollo...
We expect property companies under our coverage to maintain their stellar marketing sales achievement in 2024 with a moderate growth outlook. Despite the election in 2024 possibly translating to slower marketing sales growth, we expect marketing sales to still be supported by VAT incentives and more than 10% of 2024 marketing sales will enjoy the VAT incentives. The expectation of rate cuts in 2H24 is a re-rating catalyst for property stocks. Maintain OVERWEIGHT with CTRA as our top pick.
SMRA recorded marketing sales of Rp2.7t in 8M23, contributing to 54% of its 2023 marketing target of Rp5t. With two new malls opening (namely Summarecon Villagio Outlets in Karawang and Summarecon Mall Bandung) in 4Q23, we expect a 10% growth in its 2024 recurring revenue. We forecast 2023-24 NPAT growth of 18% yoy and 17.3% yoy respectively. The high marketing sales achievement in 2022 will translate into stronger development revenue for 2023-24. Maintain BUY with a target price of Rp820.
GREATER CHINA Strategy Small-Mid Cap Biweekly: Huawei Mate 60 introduces satellite calling; beneficiary: Zhejiang Chengchang Technology. Sector Commodities: Weekly: Better-than-expected economic figures raise hopes of soft landing. INDONESIA Update Summarecon Agung (SMRA IJ/BUY/Rp595/Target: Rp820): Remains optimistic with potential 2024 NPAT growth of 17% yoy. MALAYSIA Update Malaysia Marine and Heavy Engineering Holdings (MMHE MK/BUY/RM0.56/Target: RM0.70): Marine outlook may have moderated,...
Our research showed that the property index and top four property stocks (BSDE, CTRA, SMRA and PWON) outperformed the JCI in two out of four rate cut cycles. We expect BSDE, CTRA and SMRA to continue outperforming the JCI in 2H23 on the back of a strong marketing sales achievement in 1H23 and potential NPAT growth of 6% yoy in 2023 and 15% yoy in 2024. Maintain OVERWEIGHT. BSDE is our top pick, followed by CTRA and SMRA.
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.